Introduction {#s1}
============

Since the identification of hepatitis C virus (HCV) in the late 1980s, HCV infection has been recognized as a growing public health problem in the world. It is estimated that about 200 million people are chronically infected [@pone.0003442-Liang1]. No HCV vaccines are available to date and only a subset of patients respond to current interferon-based treatment [@pone.0003442-Liang1]. Much research effort has been focused on understanding the mechanisms of infection, persistence and clearance of HCV. Studies on hepatic gene expression in chimpanzees and humans have revealed intriguing differences between acute resolving and chronic HCV infections [@pone.0003442-Bigger1]--[@pone.0003442-Su1]. In the chimpanzee model, HCV infection induces type I IFN response and activation of a large number of interferon stimulated genes (ISGs) in the liver [@pone.0003442-Bigger1], [@pone.0003442-Su1], [@pone.0003442-Thimme1]. However, hepatic induction of type I IFN occurred in all animals irrespective of the outcome of infection [@pone.0003442-Su1], [@pone.0003442-Thimme2]. Thus, type I IFN may restrict excessive viral replication in the early phase of infection but does not seem to play a major role in subsequent viral clearance. Similar to experimentally infected chimpanzees, gene expression analysis of percutaneous liver biopsies in HCV infected humans demonstrated increased ISG expression, suggesting an ongoing host cellular response to viral infection [@pone.0003442-Helbig1]. It is not well understood why HCV is not cleared from these individuals despite the activation of potent antiviral ISGs. It is possible that in these individuals with viral persistence, the cellular response to IFN is inefficient compared to those who clear the virus. Weak induction of the ISG antiviral state coupled with an ineffective cellular immune response could therefore promote chronicity [@pone.0003442-Bigger2].

Studies of temporal changes in gene expression are central to understanding viral clearance, persistence and hepatic injury in chronic HCV infection. The intrahepatic T cell response to HCV correlates with control of acute infection [@pone.0003442-Thimme1]. Cytokine and immunomodulatory genes, generally known to be chemotactic and/or stimulatory to various immune cells were observed to be induced within the first 6 to 8 weeks after infection [@pone.0003442-Bigger1]. Viral clearance is associated with a vigorous HCV-specific T-cell response in the liver with both cytotoxic and non-cytotoxic effector functions. However HCV persists in the majority of acutely infected patients. The mechanisms leading to the failure of HCV-specific T-cell response and viral persistence are highly complex and still not fully understood. Therefore it is important to compare the spectrum and magnitude of hepatic gene expression in individuals who spontaneously clear infection and those who progress to chronicity. In this study we examined the host response to HCV infection by applying gene expression profiling of serial liver biopsies during acute HCV infection and identified unique gene expression patterns that are associated with specific outcomes of infection.

Results {#s2}
=======

Hepatic gene expression during early stage of self-limited infection {#s2a}
--------------------------------------------------------------------

To identify differentially expressed hepatic genes associated with early stages of HCV infection, a database of expression levels was generated and queried for genes whose expression was outside a calculated 99% confidence interval at different times. Using this confidence interval, 1% of genes with the greatest-fold change or least-fold change are defined as significantly up- or down-regulated (see [Materials and Methods](#s4){ref-type="sec"}). For chimpanzee X0190 with self-limited infection, 347 genes were induced above the confidence interval (\>1.9-fold change) at 4 weeks post-infection. Some of the induced genes were related to antiviral and/or type I interferon response, consistent with ongoing HCV infection. To refine our search and to further identify genes specifically associated with the early phase of infection, the database of expression levels for X0190 was queried again for genes above the confidence interval at two time points, weeks 4 and 6 post-infection (\>1.9- and \>2.1-fold induction), and below the confidence interval at weeks 13 and 40 (\<2.2-, and \<2.4-fold induction) when the chimpanzee had cleared the infection. By using these criteria, 22 genes were significantly up-regulated, 9 of which are known to be induced by type I interferon ([Table 1](#pone-0003442-t001){ref-type="table"}). The remaining 13 genes are classified as Cellular Immune Response Related or Cell Growth/Signal Transduction Related.

10.1371/journal.pone.0003442.t001

###### Genes induced during the early phase of self-limited and persistent infections.

![](pone.0003442.t001){#pone-0003442-t001-1}

  Type I Interferon Response               Chimp X0190[a](#nt101){ref-type="table-fn"}          Chimp X0234   Chimp X0142                                                                                                                                            
  --------------------------------- ---------------------------------------------------------- ------------- ------------- ----------- ----- ----- ----------- ----------- ----- ----- ----------- ----------- ----------- ----- ----------- ----------- ----------- -----------
  G1P2                                        Interferon-stimulated protein (15 kDa)            Hs. 432233     ***8.1***    ***4.6***   0.5   0.3   ***3.1***   ***7.9***   1.5   0.5   ***7.4***   ***14***    ***6.7***   1.5   ***7.5***   ***7.4***   ***11***    ***15***
  IFI27                                       Interferon alpha-inducible protein 27             Hs. 278613     ***6.6***    ***4.4***   0.6   0.3   ***3.5***   ***7.1***   1.5   0.6   ***6.6***   ***14***    ***6.6***   1.4   ***6.7***   ***6.6***   ***11***    ***14***
  OAS3                                           2′-5′oligoadenylate synthetase 3                Hs. 56009     ***5.5***    ***5.3***   1.4   0.5   ***3.2***   ***2.3***   1.1   0.8   ***4.5***   ***4.5***      2.0      1.1   ***4.7***   ***4.5***   ***4.8***   ***4.5***
  GIP3                                 Interferon alpha-inducible protein (clone IFI-6-16)      Hs. 265827     ***4.0***    ***3.8***   0.7   0.3      0.8      ***5.3***   2.2   0.6   ***4.3***   ***5.0***      2.5      1.4   ***5.8***   ***4.3***   ***4.7***   ***5.0***
  IFIT1                               Interferon-induced protein w/tetratricopeptide repeat      Hs. 20315     ***3.8***    ***2.8***   0.6   0.9   ***3.2***   ***6.4***   0.9   0.5   ***4.3***   ***4.9***   ***6.6***   0.6   ***6.8***   ***4.3***   ***5.3***   ***4.9***
  MX1                                           Myxovirus (influenza) resistance 1               Hs. 48516     ***3.6***    ***3.8***   1.0   0.7   ***3.1***   ***2.8***   1.0   1.5   ***3.4***   ***2.8***      1.8      0.8   ***4.2***   ***3.4***   ***3.7***   ***2.8***
  B2M                                                  Beta-2-microglobulin                      Hs. 75415     ***3.2***    ***2.2***   1.4   2.0      0.8      ***3.9***   2.4   0.6   ***2.3***   ***2.2***      2.2      1.2   ***2.5***      2.3      ***2.4***   ***2.2***
  OAS2                                           2′-5′oligoadenylate synthetase 2               Hs. 432659     ***2.7***    ***2.2***   1.0   0.8      2.0      ***2.0***   1.1   1.1   ***3.2***   ***2.2***      2.1      1.3      1.1         1.3         0.9         1.1
  SP110                                       Interferon-induced protein 75 (52 kD)              Hs. 38125     ***2.7***    ***2.3***   1.3   0.7      1.4         0.9      1.3   0.8      1.8         1.3         1.3      1.3   ***3.3***   ***3.2***   ***2.4***   ***2.2***
  Cellular Immune Response                                                                                                                                                                                                                                           
  ILF3                                     Interleukin enhancer binding factor 3, 90 kD          Hs. 56583     ***3.0***    ***2.3***   1.6   0.8      1.5         0.9      1.7   1.1      1.3         1.1         0.7      1.1      1.1         1.3         0.9         1.1
  TIA1                                   Cytotoxic granule-associated RNA-binding protein        Hs. 39489     ***2.6***    ***2.2***   2.1   1.0      1.3         0.6      1.1   1.1      1.2         1.2         0.7      2.0      1.2         1.2         1.4         1.2
  Cell Growth/Signal Transduction                                                                                                                                                                                                                                    
  FOSB                                   FBJ murine osteosarcoma viral oncogene homolog B        Hs. 75678     ***10***     ***5.4***   0.4   0.3      0.7         0.4      0.4   0.7      1.2         0.6         0.6      0.6      0.8         1.2         1.1         0.6
  SMARCB                             Actin dependent regulator of chromatin (SWI/SNF related)    Hs. 59971     ***7.9***    ***4.5***   0.6   0.5      1.1         1.1      1.0   0.9      1.7         0.8         0.9      0.8      1.5         1.7         1.3         0.8
  ITGA6                                                  Integrin alpha 6                        Hs. 27730     ***6.6***    ***3.4***   1.4   0.6      0.7         1.2      1.3   1.3      1.7         1.3         1.3      1.2      1.9         1.7      ***1.9***      1.3
  JUN                                     v-jun avian sarcoma virus 17 oncogene homolog          Hs. 78465     ***4.7***    ***3.3***   0.3   0.6      0.9         0.9      1.0   0.9      1.5         0.6         0.6      0.9      0.8         1.5         0.7         0.6
  PRNP                                               Prion protein (p27--30)                     Hs. 74621     ***3.6***    ***2.1***   2.1   2.0      0.7         1.7      1.3   0.6      1.4         0.5         1.0      0.8      1.1         1.4         0.7         0.5
  ID2                                               Inhibitor of DNA binding 2                  Hs. 180919     ***3.1***    ***2.2***   0.5   0.6      0.6         0.9      0.7   0.8      2.1         1.3         1.2      1.3   ***2.4***      2.1         1.7         1.3
  JUNB                                                 Jun B proto-oncogene                     Hs. 400124     ***3.0***    ***2.8***   1.7   1.3      1.1         0.8      1.0   1.3      2.3      ***2.4***      0.9      1.3      1.8         2.3         1.6      ***2.4***
  TOB2                                                 Transducer of ERBB2                       Hs. 4994      ***2.8***    ***2.3***   1.9   0.6      1.9         1.4      1.7   2.3      2.1         1.6         1.2      1.7   ***2.6***      2.1         1.7         1.6
  PRSS21                                          Serine protease, 21 (testisin)                 Hs. 72026     ***2.5***    ***2.5***   1.6   1.0      2.3      ***2.2***   1.8   1.7   ***2.7***   ***2.6***   ***2.9***   1.4      2.1      ***2.7***   ***2.6***   ***2.6***
  TRB2                                                    GS3955 protein                         Hs. 55418     ***2.1***    ***2.2***   1.8   1.1      1.0         1.5      1.7   1.6      1.9         1.5         1.5      1.5      1.2         1.9         1.5         1.5
  ARHD                                           Ras homolog gene family, member                 Hs. 15114     ***2.0***    ***2.4***   0.8   0.8      0.9         0.8      0.9   1.1      1.3         0.9         0.9      0.9      0.9         1.3         1.1         0.9
                                                       Confidence interval                          1.9           2.1          2.2      2.4   2.5      2.0         2.6      2.4   2.5      2.0         2.6         2.4      2.2      2.5         1.9         2.0     

Expression levels of genes induced above the confidence interval at weeks 4 & 6 but below the confidence interval at weeks 13 & 40 in X0190.

The bold and italicized values represent data above the 99% confidence interval as described in the text.

Comparison of hepatic gene expression during self-limited and persistent infections {#s2b}
-----------------------------------------------------------------------------------

To determine whether a different pattern of gene expression is observed between infected chimpanzees in this subset of genes, biopsy samples from two persistently infected chimpanzees X0234 and X0142 were compared to chimpanzee X0190 ([Table 1](#pone-0003442-t001){ref-type="table"}). Within the first 8 weeks of infection, a large number of type I interferon stimulated genes (ISGs) were strongly up-regulated in all chimpanzees. Type I interferon induced genes are the first line of innate defense against viral infection and also function to prime and modulate adaptive immune response. A qualitative or quantitative difference of ISG induction could not be correlated with persistence or clearance. However several genes related to cellular immune response and cell growth/signal transduction, such as ILF3, TIA1, FOSB, JUN, ID2, were differentially induced in chimpanzee X0190.

At later time points for X0190, none of the type I interferon response genes were significantly upregulated, consistent with the clearance of viremia and resolution of infection. Interestingly, a similar gene expression pattern was also observed for the persistently infected chimps. In X0234, some of these genes that were induced earlier returned to baseline at week 10, but became elevated again at week 12 post-infection. It has been shown that acutely infected chimpanzees and humans can have markedly fluctuating levels of viremia during the acute phase, possibly indicating transient control of viral infection [@pone.0003442-Fernandez1]--[@pone.0003442-SmykPearson1]. This transient control could explain the lack of continuous induction of ISGs at certain time points. In particular, the viral level of X0234 at week 8 was 4000 genomes/mL, week 10 was 600 genomes/mL (borderline detection), and week 12 was 7000 genomes/mL. Additional biopsy samples from one of these animals, X0142, were collected at much later time points during the chronic phase ([Fig. 1](#pone-0003442-g001){ref-type="fig"}). Up-regulation of many ISGs was again observed, suggesting the establishment of chronic infection. This observation is consistent with previous publications [@pone.0003442-Bigger2], [@pone.0003442-Su1].

![Chimpanzee inoculation and biopsy schedule.\
Chimpanzees were inoculated with RNA transcript of the molecular clone HCV-CG1b or infectious serum from the same clone (○). The course of infection has been described previously (Thomson et al., 2001). The level of viremia is shown as either positive (+) negative (−). Biopsy samples were taken at various time points after inoculation (↓) and used for microarray analysis X0190, X0234 and X0142). RNA samples from weeks 8 and 10 of X0190 were not of adequate quality for microarray analysis.](pone.0003442.g001){#pone-0003442-g001}

As an alternative approach to identify genes induced during the early stage of infection that could be associated with clearance, the average expression profile of persistently infected chimpanzees (X0234 and X0140) was compared to the average expression profile of chimp X0190 during weeks 4 and 6. We reasoned that any difference between the two groups of animals, if significant, might be more easily detected by averaging the gene expression values during this time frame. Furthermore, we might identify a different set of induced genes compared to our previous analysis (e.g. genes whose fold-induction levels were within the confidence interval for at least one time point but were on average higher during the acute phase of infection).

During the first eight weeks of self limited infection (X1090) we found 36 known genes induced 2.5-fold or greater over those during persistent infection (X0234 and X0140). The averaged ratios of induction are shown in [Table 2](#pone-0003442-t002){ref-type="table"}. Six of these genes were also found on the list of the previous analysis of chimpanzee X0190 at weeks 4 and 6 ([Table 1](#pone-0003442-t001){ref-type="table"}).

10.1371/journal.pone.0003442.t002

###### Genes induced during the early phase of self-limited infection as defined by average expression values.

![](pone.0003442.t002){#pone-0003442-t002-2}

  Title                                                  Clone description                                             UG cluster     Self-limited infection[a](#nt103){ref-type="table-fn"}   Persistent infection[a](#nt103){ref-type="table-fn"}   Ratio of induction
  ------------ ----------------------------------------------------------------------------------------------------- --------------- -------------------------------------------------------- ------------------------------------------------------ --------------------
  **FOSB**                             **FBJ murine osteosarcoma viral oncogene homolog B**                           **Hs.75678**                           **7.54**                                                **0.77**                              **9.77**
  DCT                     Dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2)               Hs.301865                              6.55                                                    0.69                                  9.44
  **SMARCB**                       **Actin dependent regulator of chromatin (SWI/SNF related)**                       **Hs.159971**                          **6.04**                                                **0.64**                              **9.41**
  EGR1                                                Early growth response 1                                            Hs.738                                2.50                                                    0.30                                  8.20
  ETR101                                              Immediate early protein                                            Hs.737                                8.02                                                    1.19                                  6.75
  RPS4Y                                           Ribosomal protein S4, Y-linked                                        Hs.180911                              8.46                                                    1.40                                  6.02
  **JUN**                                **v-jun avian sarcoma virus 17 oncogene homolog**                            **Hs.78465**                           **3.99**                                                **0.76**                              **5.21**
  CYP1A1                     Cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1                  Hs.72912                               2.18                                                    0.48                                  4.51
  SCYA3                              Small inducible cytokine A3 (homologous to mouse Mip-1a)                           Hs.73817                               1.23                                                    0.29                                  4.28
  PEX1                                            Peroxisome biogenesis factor 1                                        Hs.99847                               3.68                                                    0.90                                  4.09
  KIAA0855                                                   Golgin-67                                                  Hs.182982                              2.01                                                    0.54                                  3.75
  SARS                                                 Seryl-tRNA synthetase                                             Hs.4888                               1.13                                                    0.31                                  3.68
  GLO1                                                     Glyoxalase I                                                 Hs.75207                               4.14                                                    1.14                                  3.63
  **ITGA6**                                            **Integrin alpha 6**                                           **Hs.227730**                          **4.79**                                                **1.35**                              **3.55**
  DUSP1                                           Dual specificity phosphatase 1                                        Hs.171695                              2.31                                                    0.68                                  3.41
  **PRNP**                                          **Prion protein (p27--30)**                                       **Hs.74621**                           **2.79**                                                **0.87**                              **3.21**
  RUVBL2                                           RuvB (E coli homolog)-like 2                                          Hs.6455                               1.80                                                    0.58                                  3.10
  SCYA3L1                                       Small inducible cytokine A3-like 1                                      Hs.274535                              0.97                                                    0.31                                  3.10
  TRF4                                      Topoisomerase-related function protein 4-1                                  Hs.225951                              1.73                                                    0.57                                  3.03
  CALML3                                                 Calmodulin-like 3                                              Hs.239600                              2.96                                                    1.01                                  2.94
  GCN1L1                          GCN1 (general control of amino-acid synthesis 1, yeast)-like 1                        Hs.75354                               1.58                                                    0.55                                  2.89
  SCD                                      Stearoyl-CoA desaturase (delta-9-desaturase)                                 Hs.119597                              1.16                                                    0.40                                  2.88
  ATP2B2                                   ATPase, Ca++ transporting, plasma membrane 2                                 Hs.89512                               1.40                                                    0.49                                  2.86
  CYP4F3                 Cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase)               Hs.106242                              2.94                                                    1.05                                  2.80
  COL7A1              Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)            Hs.1640                               1.58                                                    0.57                                  2.78
  SLC6A3                    Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3                   Hs.406                                2.57                                                    0.95                                  2.70
  KLF4                                              Kruppel-like factor 4 (gut)                                          Hs.7934                               2.23                                                    0.83                                  2.67
  **ILF3**                               **Interleukin enhancer binding factor 3, 90 kD**                             **Hs.256583**                          **2.63**                                                **1.00**                              **2.62**
  **ID2**                                         **Inhibitor of DNA binding 2**                                      **Hs.180919**                          **2.64**                                                **1.02**                              **2.58**
  ZNF216                                              Zinc finger protein 216                                            Hs.3776                               1.07                                                    0.41                                  2.57
  NR1I2                                   Nuclear receptor subfamily 1, group I, member 2                               Hs.118138                              1.89                                                    0.74                                  2.56
  **TIA1**                           **TIA1 cytotoxic granule-associated RNA-binding protein**                        **Hs.239489**                          **2.40**                                                **0.94**                              **2.56**
  CDK9                                    Cyclin-dependent kinase 9 (CDC2-related kinase)                               Hs.150423                              1.66                                                    0.66                                  2.52
  RELA          v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypepti     Hs.75569                               1.79                                                    0.71                                  2.52
  EPHX2                                          Epoxide hydrolase 2, cytoplasmic                                        Hs.113                                2.50                                                    1.00                                  2.51
  CYP4F2                                   Cytochrome P450, subfamily IVF, polypeptide 2                                 Hs.101                                1.99                                                    0.79                                  2.51

Average expression values of biopsies taken during the 1^st^ 8 weeks of infection.

Bold-face genes are also in [Table 1](#pone-0003442-t001){ref-type="table"}.

Hepatic gene expression during the clearance phase of self-limited infection {#s2c}
----------------------------------------------------------------------------

To identify genes that may be specifically induced during viral clearance in chimpanzee X0190, the database of expression levels was queried for genes above the confidence interval at 13 weeks post-infection (\>2.2-fold induction) and below this interval at 4, 6 and 40 weeks (\<1.9-, 2.1-, and 2.4-fold induction). Forty-four genes were significantly up-regulated at 13 weeks ([Table 3](#pone-0003442-t003){ref-type="table"}). Twenty of these were associated with activation of cellular immunity and as such were classified as Cellular Immune Response-related. Consistent with the previous observation of active HCV-specific T-cell response in biopsy specimens during resolving infections, we found evidence for a vigorous immune response involving induction of CD8+ T-cell markers (CD8 antigen and components of the T-cell receptor) and effectors of CD8+ T cells (granzyme A and interferon-gamma) in X0190. The remaining 25 genes significantly induced at 13 weeks could be classified as Cell Growth/Signal Transduction-related ([Table 3](#pone-0003442-t003){ref-type="table"}).

10.1371/journal.pone.0003442.t003

###### Genes induced during the clearance phase of self-limited infection.

![](pone.0003442.t003){#pone-0003442-t003-3}

  Cellular Immune Response                  Chimp X0190[a](#nt105){ref-type="table-fn"}          Chimp X0234   Chimp X0142                                                                                                                                                              
  --------------------------------- ----------------------------------------------------------- ------------- ------------- ----- ----------- ----- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  GZMA                                                      Granzyme A                            Hs.90708         1.3       1.7   ***6.5***   1.5      1.2         2.5         1.8         1.7      ***5.6***      1.3         2.5      ***4.7***      1.7      ***5.6***   ***2.2***      1.3
  CD3D                                            CD3D antigen, delta polypeptide                 Hs.95327         1.7       2.0   ***6.4***   2.0      1.3      ***2.7***   ***2.4***      1.7      ***3.9***      1.2         1.7      ***3.6***   ***2.5***   ***3.9***   ***2.1***      1.2
  IGL                                               Immunoglobulin lambda locus                   Hs.05944         1.7       2.1   ***5.8***   2.0   ***3.2***   ***3.3***   ***6.0***   ***4.2***   ***2.5***   ***5.0***      1.4      ***3.9***      1.7      ***2.5***   ***5.6***   ***5.0***
  CD8B1                                        CD8 antigen, beta polypeptide 1 (p37)               Hs.2299         1.4       1.8   ***5.6***   1.3      1.3         1.9      ***2.0***      1.6         1.6         1.4         1.2         1.8         1.3         1.6         1.6         1.4
  CCL5                                         Small inducible cytokine A5 (RANTES)               Hs. 41392        0.9       1.1   ***4.8***   1.0      1.3         1.7      ***2.7***      2.8         2.7      ***2.4***      1.0         2.2      ***2.7***   ***2.7***   ***2.2***   ***2.4***
  TRA                                        Human T-cell receptor active alpha-chain             Hs.74647         1.8       1.7   ***4.5***   1.4      1.9      ***5.1***   ***4.2***      3.1         2.6      ***2.4***   ***3.0***   ***4.2***      1.8      ***2.6***   ***3.3***   ***2.4***
  CSF2RA                                       Colony stimulating factor 2 receptor               Hs. 82378        1.3       1.9   ***4.0***   1.7   ***2.4***      1.4      ***3.1***   ***4.3***      1.9      ***2.8***      1.1      ***3.2***   ***3.3***      1.9      ***2.1***   ***2.8***
  KLRB1                                    Killer cell lectin-like receptor subfamily B           Hs.69824         1.9       2.1   ***3.9***   2.1      1.0         2.6         1.6         1.1      ***3.6***      1.0         1.6         0.9      ***2.5***   ***3.6***      1.7         1.0
  CD8A                                         CD8 antigen, alpha polypeptide (p32)               Hs.85258         1.6       1.4   ***3.5***   1.4      0.8         1.6         1.7         1.4         2.0         1.1         0.8         1.5         1.6         2.0         1.1         1.1
  IGHG3                                        Immunoglobulin heavy constant gamma 3              Hs.413826        1.6       1.6   ***3.4***   1.0   ***2.5***      2.3      ***3.2***   ***3.3***   ***2.6***   ***2.8***      1.0      ***3.0***      1.8      ***2.6***   ***5.0***   ***2.8***
  CD2                                                    CD2 antigen (p50)                        Hs.89476         1.9       1.3   ***3.3***   1.4      1.3      ***5.6***   ***4.0***      2.0      ***2.6***      1.9         2.0      ***3.3***   ***3.0***   ***2.6***   ***2.4***      1.9
  TRGV9                                             T cell receptor gamma locus                   Hs.12259         1.2       1.9   ***3.0***   1.8      1.6      ***3.2***   ***3.2***      1.6      ***2.8***      1.8         1.5         1.6         1.6      ***2.8***   ***2.2***      1.8
  ITK                                               IL2-inducible T-cell kinase                   Hs.11576         1.7       1.7   ***3.0***   1.2      1.1         2.6      ***2.2***      1.4         1.7         1.6         1.6         1.6         1.9         1.7         1.5         1.6
  SELPLG                                                 Selectin P ligand                        Hs.79283         1.5       1.6   ***2.8***   1.3      1.6      ***2.9***   ***2.8***      3.0      ***2.6***      1.7         1.2      ***2.6***   ***2.7***   ***2.6***      1.5         1.7
  VIL2                                                   Villin 2 (ezrin)                         Hs.155191        1.1       1.8   ***2.4***   1.5      1.8         1.4      ***2.8***      2.2         2.3      ***2.2***      1.4         1.4         1.9         2.2         2.3         1.3
  RI58                                Retinoic acid- and interferon-inducible protein (58 kD)     Hs.27610         0.7       0.9   ***2.4***   0.7      0.8         0.6         0.8         0.7         0.8         0.7         0.7         0.5         0.8         0.8         0.8         0.7
  IFNG                                                   Interferon gamma                          Hs.856          1.2       1.6   ***2.4***   1.3      1.1         1.5         1.6         1.2         1.8         1.1         1.1         1.3         1.6         1.8         1.7         1.1
  TANK                                     TRAF family member-associated NFKB activator           Hs.146847        1.3       1.5   ***2.3***   2.1      1.5         1.5         1.5         1.5         1.5         1.1         1.6         1.3         1.6         1.5         1.7         1.1
  TNFRSF1A                                      Tumor necrosis factor receptor (1A)                Hs.159          1.6       1.2   ***2.3***   1.1   ***3.7***      0.6         1.9      ***3.6***      1.1         1.5         0.6         1.5         1.2         1.1         1.4         1.5
  PADI4                                        Peptidyl arginine deiminase (type IV)              Hs.117232        0.8       1.3   ***2.2***   1.7      1.7         1.1         1.1         2.4         2.0         1.7         1.2         1.2         1.6         2.0         1.3         1.7
  Cell Growth/Signal Transduction                                                                                                                                                                                                                                                       
  SFTPA2                                   Surfactant (pulminory-associated protein A1)           Hs.177582        1.2       1.4   ***3.6***   1.2      1.9         1.5         1.8         2.8         2.0         1.9         1.1         1.7         1.8         2.0         1.3         1.9
  UBD                                                       Diubiquitin                           Hs.44532         0.9       0.6   ***3.3***   0.5      1.8      ***4.5***   ***3.4***      2.9         2.3         1.4         1.2         1.5         1.5         2.3         1.4         1.4
  HOXB5                                                    Homeo box B5                           Hs.22554         1.1       1.7   ***3.2***   1.6      1.9         1.1      ***2.5***      3.2         1.1      ***2.6***      0.9         2.0      ***2.3***      1.1         1.8         1.6
  BAZ2B                                   Bromodomain adjacent to zinc finger domain, 2B           Hs.8383         1.6       1.2   ***3.0***   0.8      1.4         1.0         0.9         2.0         1.0         0.9         0.8         1.4         1.2         1.0         1.0         0.9
  AF1Q                                          ALL1-fused gene from chromosome 1q                Hs.75823         1.8       2.0   ***2.6***   2.1   ***4.7***   ***4.6***   ***2.4***      2.8      ***4.5***   ***2.4***   ***3.9***   ***2.5***      2.1      ***4.5***   ***2.3***   ***2.2***
  ITM2A                                            Integral membrane protein 2A                   Hs.17109         1.0       1.4   ***2.6***   1.7      1.1         1.8         1.3         1.5      ***2.7***      1.5         1.3         2.3         1.6      ***2.7***      1.5         1.5
  ANXA6                                                     Annexin A6                            Hs.118796        1.0       1.4   ***2.5***   1.4   ***2.2***      2.0         2.0      ***5.0***   ***3.3***      1.3         0.9         2.3      ***2.8***   ***3.3***   ***2.0***      1.3
  SFRS3                                       Splicing factor, arginine/serine-rich 3             Hs.388623        1.8       1.8   ***2.5***   1.7   ***2.4***      2.1         1.9         2.9         1.5         0.9         1.5         2.1         2.1         1.5         1.2         0.9
  AMY2A                                            Amylase, alpha 2A; pancreatic                  Hs.300280        1.2       1.6   ***2.5***   1.5      1.5         0.9         1.2         1.9         0.8         1.2         0.4         1.0         1.3         0.8         0.8         1.2
  KIF22                                                   Kinesin-like 4                          Hs.119324        1.4       0.9   ***2.5***   1.7   ***2.5***   ***3.3***   ***2.1***   ***3.9***      1.3         1.1      ***2.6***      2.2         1.2         1.3         1.2         1.1
  CAPON                                      Ligand of neuronal nitric oxide synthase             Hs.129729        1.7       1.6   ***2.5***   1.2   ***2.5***      0.4         0.8         2.3         1.3      ***2.0***      0.5      ***2.6***      1.4         1.3      ***2.1***   ***2.0***
  COX5B                                          Cytochrome c oxidase (subunit Vb)                 Hs.1342         1.4       1.0   ***2.5***   1.8      1.2      ***3.8***      1.7         1.7         1.6         1.0         2.4         1.2         1.9         1.6         1.7         1.0
  LGALS1                                      Galactoside-binding lectin (galectin 1)             Hs.382367        1.6       1.2   ***2.4***   2.0      1.3      ***3.3***   ***2.9***      1.3         1.9         1.0         1.4         1.3      ***2.5***      1.9      ***2.3***      1.0
  MBL1P1                                       Mannose-binding lectin, pseudogene 1               Hs.116218        1.7       1.6   ***2.4***   1.6      1.2         0.6         0.8         1.1         1.4      ***2.4***      0.8         2.1         1.1         1.4         1.3      ***2.4***
  GNG3                                          Guanine nucleotide binding protein                Hs.179915        1.5       1.4   ***2.4***   2.1      1.7         1.7      ***2.4***      2.9         1.7         1.2         1.3         2.3         2.0         1.7         1.8         1.2
  RBBP4                                          Retinoblastoma-binding protein 4                 Hs.16003         1.2       1.3   ***2.4***   1.7      1.2         1.1         1.0         1.7         1.7         1.2         1.7         1.2         1.4         1.7         1.4         1.2
  CHI3L1                                  Chitinase 3-like 1 (cartilage glycoprotein-39)          Hs.75184         0.9       1.6   ***2.4***   1.9      1.5         1.5         1.1         2.7         1.2         1.6         0.9         0.9      ***2.3***      1.2         1.1         1.6
  NESG1                                    Nasopharyngeal epithelium specific protein 1           Hs.158450        0.6       1.5   ***2.3***   1.6      1.1         1.1         0.8         3.2         1.2         1.2         0.7         1.1      ***2.5***      1.2         1.0         1.2
  CBLC                                        Cas-Br-M Murine retroviral transforming             Hs.156637        0.6       1.5   ***2.3***   1.6      1.2         0.9         0.8      ***3.7***      1.5         1.4         1.2         1.1      ***3.8***      1.5         1.8         1.4
  SLC21A6                                            Solute carrier family 21                     Hs.137425        1.4       1.1   ***2.3***   1.1   ***3.5***      0.6         1.8      ***4.3***      1.1         1.3         0.5         1.4         1.0         1.1         1.2         1.3
  DSS1                                       Deleted in split-hand/split-foot 1 region            Hs.333495        1.2       1.0   ***2.3***   1.5      1.2         1.2         1.2         1.1         1.8         1.2         2.2         1.0         1.4         1.8         1.5         1.2
  BAIAP1                                             BAI1-associated protein 1                    Hs.169441        1.1       1.3   ***2.3***   1.2      1.2      ***8.0***      1.1         1.4         1.8      ***2.0***      0.7         1.4         1.3         1.8         1.3      ***2.0***
  PCAF                                            PCAF associated factor 65 beta                  Hs.26782         1.7       1.7   ***2.2***   1.3   ***2.2***      2.4      ***2.8***      2.1         1.3         0.9         0.8         1.1         1.1         1.3         0.7         0.9
  EIF2AK3                            Eukaryotic translation initiation factor 2-alpha kinase 3    Hs.102506        1.5       1.4   ***2.2***   1.3      1.0         0.9         0.8         1.1         1.3         1.1         0.8         2.1         1.0         1.3         1.2         1.1
                                                      99% confidence interval                                      1.9       2.1      2.2      2.4      2.1         2.7         2.0         3.3         2.5         2.0         2.6         2.4         2.2         2.5         1.9         2.0

Expression levels of genes induced above the confidence interval at week 13 but below the confidence interval at weeks 4, 6 & 40 of X0190.

The bold and italicized values represent data above the 99% confidence interval as described in the text.

To discern additional differences between the self-limited and chronically infected chimpanzees, the averaged expression profiles of the two persistently infected chimpanzees (X0142 and X0234) from weeks 10 to 12 were compared to those of chimpanzee X0190 during clearance (week 13). We reason that viral clearance may be associated with a distinct set of gene expression in the liver. By comparing the gene expression profiles at about the same time when the chimpanzee is undergoing viral clearance to those of chimpanzee who is not could provide valuable insight into the mechanism of viral clearance. During this phase, 20 known genes of X0190 were induced 2.5-fold or greater over the average values of the equivalent time points of X0142 and X0234 ([Table 4](#pone-0003442-t004){ref-type="table"}). Of these, 5 genes are also in [Table 3](#pone-0003442-t003){ref-type="table"}.

10.1371/journal.pone.0003442.t004

###### Genes induced during the clearance phase of self-limited infection as defined by average expression values.

![](pone.0003442.t004){#pone-0003442-t004-4}

  Title                                       Clone description                                    UG cluster     Self-limited infection[a](#nt107){ref-type="table-fn"}   Persistent infection[b](#nt108){ref-type="table-fn"}   Ratio of induction
  ----------- ---------------------------------------------------------------------------------- --------------- -------------------------------------------------------- ------------------------------------------------------ --------------------
  RPS4Y                                 Ribosomal protein S4, Y-linked                              Hs.180911                             12.66                                                    1.64                                  7.72
  GLO1                                           Glyoxalase I                                       Hs.268849                              4.07                                                    0.75                                  5.41
  NPTX1                                      Neuronal pentraxin I                                   Hs.84154                               1.45                                                    0.40                                  3.59
  **RI58**               **Retinoic acid- and interferon-inducible protein (58 kD)**              **Hs.252839**                          **2.40**                                                **0.70**                              **3.42**
  UK114                             Translational inhibitor protein p14.5                           Hs.18426                               2.00                                                    0.59                                  3.40
  AMHR2                            Anti-Mullerian hormone receptor, type II                         Hs.437877                              0.97                                                    0.30                                  3.19
  **CD8B1**                       **CD8 antigen, beta polypeptide 1 (p37)**                        **Hs.2299**                           **5.57**                                                **1.76**                              **3.16**
  **KLRB1**               **Killer cell lectin-like receptor subfamily B, member 1**              **Hs.169824**                          **3.89**                                                **1.24**                              **3.13**
  APOF                                         Apolipoprotein F                                      Hs.2388                               1.00                                                    0.32                                  3.12
  KIAA0855                                        Golgin-67                                         Hs.182982                              1.60                                                    0.54                                  2.95
  TSNAX                                  Translin-associated factor X                               Hs.96247                               1.81                                                    0.63                                  2.89
  FKBP5                                    FK506-binding protein 5                                   Hs.7557                               2.69                                                    0.94                                  2.87
  NNMT                                 Nicotinamide N-methyltransferase                             Hs.364345                              2.07                                                    0.76                                  2.73
  NUP153                                      Nucleoporin 153 kD                                    Hs.146449                              1.95                                                    0.72                                  2.71
  SOCS3                               Supressor of cytokine signaling 3                             Hs.436943                              2.54                                                    0.94                                  2.69
  **CD3D**                           **CD3D antigen, delta polypeptide**                          **Hs.95327**                           **6.44**                                                **2.42**                              **2.66**
  CALML3                                      Calmodulin-like 3                                     Hs.239600                              3.37                                                    1.28                                  2.63
  ARF3                                  Human ADP-ribosylation factor                               Hs.22012                               1.40                                                    0.54                                  2.58
  **GZMA**     **Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)**   **Hs.90708**                           **6.48**                                                **2.56**                              **2.53**

Expression value of biopsy taken at 13 weeks of infection.

Average expression values of biopsies taken during the 10 and 12 weeks of infection.

Bold-face genes are also in [Table 1](#pone-0003442-t001){ref-type="table"}.

Quantitative PCR confirmation of selected genes {#s2d}
-----------------------------------------------

To confirm the microarray data, TaqMan real-time PCR was performed on selected genes from each analysis. For ISGs, GIP2 and IFIT1 were analyzed. Among the genes identified in [Tables 1](#pone-0003442-t001){ref-type="table"} and [2](#pone-0003442-t002){ref-type="table"}, ILF3, TIA1, ID2 and JUN were selected for quantitative PCR. In addition, serial liver biopsy RNAs from another chimpanzee that developed chronic infection after inoculation with a different HCV strain (H77 1a) were analyzed. The data in general support the microarray results. The ISG expression varied among the chimpanzees, but showed no significant difference between self-limited and chronic infections. The genes (ILF3, TIA1, ID2 and JUN) identified to be different by microarray during the early phase of HCV infection between the two groups were confirmed by quantitative PCR. Their expression levels were 10 to 100-fold higher in X0190 than those of other three chimpanzees.

Discussion {#s3}
==========

HCV infection can lead to a high rate of chronicity, with 70--80% of infected persons developing persistent infection [@pone.0003442-Liang1]. The mechanisms by which HCV establishes chronic infection have been the subject of intense research. Failure of HCV-specific immune response, particularly of the T cells, has been proposed as the cause of chronicity [@pone.0003442-NeumannHaefelin1], [@pone.0003442-Rehermann1]. Studies in humans and chimpanzees have shown that T cell-mediated immunity is important for viral clearance [@pone.0003442-Bowen1], [@pone.0003442-Kaplan1]. However, the pivotal question remains as to how the host immune response fails during the acute HCV infection so it can no longer control the virus, resulting in persistent infection. Thus it is crucial to define the molecular and cellular mechanisms by which the antiviral host response is activated and regulated during the early stage of acute HCV infection. Furthermore, because the major site of viral tropism is the liver, it is essential to study these events in the liver. One approach to elucidate this complicated process is to study the global gene expression profile in the liver during the acute phase of viral infection, and to discern unique patterns that are associated with either viral clearance or progression to chronic infection.

We previously reported the infection of three chimpanzees with an infectious HCV genotype 1b clone; one had acute self-limited infection and the other two developed chronic infection [@pone.0003442-Thomson1]. We reported that regardless of the outcome of infection, peripheral T-cell responses were weak and comparable among the chimpanzees during the course of infection; however, intrahepatic T-cell response was not analyzed [@pone.0003442-Thomson2]. In this study, serial liver biopsies were available in these chimpanzees and were used for cDNA microarray analysis. Analysis of these gene expression patterns revealed that a type I interferon response was induced during the early phase (4--8 weeks) of infection in all chimpanzees regardless of the outcome of infection. Various well-defined interferon stimulated genes were up-regulated in all the liver samples. This observation is consistent with previous studies describing that type I interferon response is rapidly induced in the liver in response to HCV infection [@pone.0003442-Bigger1], [@pone.0003442-Su1].

Interestingly, several genes were specifically induced in the recovered chimpanzee during the early phase of infection but not in those chimpanzees with chronic infection. Two of the genes are interleukin enhancer binding factor 3 (ILF3) and cytotoxic granule-associated RNA binding protein (TIA1). This difference was also confirmed by quantitative RT-PCR ([Fig. 2](#pone-0003442-g002){ref-type="fig"}). Both of them are related to cellular immune response and may potentially herald the emergence of a robust T-cell response later. The other genes could be functionally clustered into cell growth/signal transduction pathways. Genes such as FOSB, JUN, JUNB, and ID2 ([Tables 1](#pone-0003442-t001){ref-type="table"} and [2](#pone-0003442-t002){ref-type="table"}) are typically associated with the immediate early genes during liver regeneration [@pone.0003442-Natarajan1], [@pone.0003442-Sandoval1]. Several studies reported that ID2 (Inhibitor of DNA binding or Differentiation) protein, a helix-loop-helix transcription factor, has important roles in cell growth, differentiation and angiogenesis [@pone.0003442-Damdinsuren1], [@pone.0003442-Tsunedomi1]. ID2 is also essential for NK lineage commitment from bipotent progenitors of both T and NK cells [@pone.0003442-Fujimoto1]. Other up-regulated genes including EGR1, ETR101, CDK9 and RelA, are also related to cell growth and proliferation [@pone.0003442-AhmedChoudhury1]--[@pone.0003442-Shore1]. Induction of EGR1 and ETR101 is also part of the early proliferative response in the liver. In addition, EGR1 is involved in the induction of FasL in T cells [@pone.0003442-Droin1] and the ETR101 has been implicated in T cell proliferation and maturation [@pone.0003442-Ollila1]. These two genes might represent the induction of a successful T cell response against HCV in chimpanzee X0190 but not in X0142 and X0234. The induction of these genes may signify the initial phase of hepatocyte injury and proliferation, despite the absence of aminotransferase elevation and liver pathology during this stage of infection. This observation has implication with respect to the induction of adaptive immunity that is important for the subsequent control of viral infection. This pattern of gene expression in the liver may represent a successful "danger signal" that has been proposed to be a trigger for adaptive immunity. The lack of induction of these genes in chimpanzees that progress to chronic infection may actually represent a failure to amplify anti-viral T-cell response. This intriguing hypothesis awaits further studies to clarify the role of these genes during HCV infection.

![Real-time PCR quantification of candidate genes involved in viral clearance and persistence.\
TaqMan real-time PCR was performed as described in [Materials and Methods](#s4){ref-type="sec"}. The y-axis shows the relative unit of a given gene normalized to GAPDH and 18s rRNA. Data are expressed as means±SEM. In all cases, average values obtained during the first eight weeks of infection were compared between recovered (X0190) and chronically infected chimpanzees (X 0234, X0142 and X6412). \* *P\<0.05*, \*\* *P\<0.01*, \*\*\* *P\<0.01*, \*\*\*\* *P\<0.005*.](pone.0003442.g002){#pone-0003442-g002}

During acute HCV infection, a rapid IFN response limits virus replication and spread in the liver until virus-infected hepatocytes are cleared by specific T-cell immune response [@pone.0003442-Bigger2]. Analysis of gene expression patterns during the viral clearance phase of chimpanzee X0190 reveals the intrahepatic induction of cellular immune response. This is particularly evident with markers of CD8+ T cell response including granzyme A, CD8 antigen, T cell receptors, and interferon-gamma ([Table 3](#pone-0003442-t003){ref-type="table"}). On the other hand, fewer of these genes were induced and at a lower magnitude in chimpanzees with chronic infection. These findings are consistent with a recent study on hepatic gene expression in chimpanzees during acute HCV infection [@pone.0003442-Bigger1], [@pone.0003442-Su1], and support the importance of T cell immune response in controlling HCV infection [@pone.0003442-Cooper1]--[@pone.0003442-Lechner1], [@pone.0003442-NeumannHaefelin1], [@pone.0003442-Takaki1], [@pone.0003442-Thimme1]. Other genes that were preferentially induced during the clearance phase are diverse. They do not overlap with those genes induced during the early phase of infection and may represent a more complex array of molecular and cellular events during viral clearance. All these genes returned to baseline expression after viral clearance. In contrast, many ISGs remained elevated in chimpanzees with chronic infection, indicating an ongoing type I IFN response to persistent HCV infection.

In this study, molecular profiling of gene expression patterns in chimpanzees with serial liver biopsies during the course of infection provides valuable information on the potential mechanisms of viral clearance and persistence. Although the number of animals is small, we are able to define a unique gene expression pattern associated with viral clearance and demonstrate the potential importance of induction of certain genes in a "successful" anti-HCV response. IFN-stimulated genes (ISGs) are induced similarly regardless of the outcome of infection. Early induction of a set of genes associated with cell proliferation and immune activation appears to be involved in subsequent viral clearance. Furthermore, evidence for a strong intrahepatic induction of cellular immune response in chimpanzees associated with self-limited infection is present. These findings support the importance of T-cell immune response in controlling HCV infection. Additional studies in other chimpanzees or humans with well-characterized course of acute infection are necessary to confirm these observations.

Materials and Methods {#s4}
=====================

Animals {#s4a}
-------

Chimpanzees *(Pan troglodyte)* were housed at the Southwest Foundation for Biomedical Research, an Association for Assessment and Accreditation of Laboratory Animal and Care (AAALAC)-accredited facility, and the study protocol was approved by the Institutional Animal Care and Use Committee at the Foundation and by the Interagency Animal Model Committee at the National Institutes of Health. Three chimpanzees (X0190, X0142 and X0234) were infected with HCV CG1b strain, either by intrahepatic inoculation of HCV RNA or HCV-positive serum, as described previously [@pone.0003442-Thomson1]. One animal X0190 recovered from the infection and the other two (X0142 and X0234) developed chronic infection. The infection courses of all three chimpanzees have been described in detail previously [@pone.0003442-Thomson1], [@pone.0003442-Thomson2] and summarized in [Fig. 1](#pone-0003442-g001){ref-type="fig"} with time points of liver biopsy. Another chimpanzee X6412 was infected with H77 1a strain and developed chronic infection [@pone.0003442-Major1]. Serial liver biopsies of this chimpanzee were provided by Stephen Feinstone of FDA.

RNA extraction and microarray expression analysis {#s4b}
-------------------------------------------------

RNA was isolated from liver biopsies (about 20 mg of liver tissue which gives 10--15 µg of total RNA) of the chimpanzees. Deposition cDNA microarrays containing 8703 features were generated from IMAGE clones (ResGen, Huntsville, AL) as described previously [@pone.0003442-Khan1], [@pone.0003442-Khan2]. Liver biopsies were extracted directly with Trizol (Invitrogen, Carlsbad, CA) and Dounce homogenization. Following chloroform extraction, RNA samples were further purified with RNeasy columns (Qiagen, Valencia, CA). 5--20 µg total RNA was typically isolated from each liver biopsy and 5 µg of RNA was amplified using a RiboAmp protocol (Arcturus Bioscience Inc, Mountain View, California). A single round of amplification yielded approximately 60 µg of polyA-selected RNA, of which 2.5 µg was labeled by using the CyScribe first-strand cDNA and labeling protocol (Amersham/Pharmacia, Piscataway, New Jersey). Briefly, RNA was reverse transcribed to produce Cy-5 labeled cDNA while Cy-3 labeled cDNA was made in a similar manner from pre-infection or uninfected reference liver RNA. Individual Cy-5 labeled samples were mixed with the Cy-3 labeled reference and hybridized overnight at 65°C in an aqueous based hybridization solution. Detailed RNA isolation, labeling and hybridization protocols are available at <http://research.nhgri.nih.gov/microarray/>. Slide images were acquired by an Agilent scanner (Agilent Technologies, Palo Alto, CA). Gene assignments and expression data were extracted using the DeArray Suite [@pone.0003442-Chen1] for IPLab spectrum. The resulting data was downloaded to FileMaker Pro (FileMaker Inc., Santa Clara, CA). Phenotype averaging was performed using the BRB array tools, developed by the Biometrics Research Branch, Division of Cancer Treatment and Diagnosis and available to download on the web: <http://linus.nci.nih.gov/BRB-ArrayTools.html>

Real-time Quantitative PCR {#s4c}
--------------------------

Real-time quantitative PCR was used to confirm the microarray findings. Complementary DNA (cDNA) was synthesized from total RNA (isolated from liver biopsy samples) with First-strand cDNA Synthesis System (Marligen Biosciences, Ijamsville, MD). In addition, we analyzed serial liver biopsy samples from a chronically infected chimpanzee (X1602, infected with genotype 1a H77 strain) by TaqMan PCR quantification of selected genes of interest. The primers and probes used were obtained from Gene Expression Assays (Applied Biosystems, Foster City, CA). Each reaction was performed in duplicate, and all samples were standardized using the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene and 18S rRNA. Reactions were set up with 12.5 µL TaqMan universal PCR master mix, cDNA template, and 1.25 µL primers and probe mix in a final volume of 25 µL. Reactions were performed on an iCycler iQ Multicolor Real-Time Detection System (Bio-Rad, Hercules, CA) with the following reaction conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 20 sec, 60°C for 1 min, and additional incubation at 68°C for 10 min.

Statistical Analysis {#s4d}
--------------------

The overall significance was assessed by 1-way ANOVA and significant difference between groups was assessed by the Student\'s *t*-test.
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